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patient-reported outcome-based performance measures (PRO-PMs) of
symptoms, functional status, and quality of life. Methods: A Techni-
cal Expert Panel was assembled by the American Medical Association–
convened Physician Consortium for Performance Improvement. An
environmental scan and structured literature review were conducted
to identify quality programs that integrate PRO-PMs. Key methodo-
logical considerations in the design, implementation, and analysis of
these PRO-PM data were systematically identiﬁed. Recommended
methods for addressing each identiﬁed consideration were developed
on the basis of published patient-reported outcome (PRO) standards
and reﬁned through public comment. Literature review focused on
programs using PROs to assess performance and on PRO guidance
documents. Results: Thirteen PRO programs and 10 guidanceee front matter Copyright & 2015, International S
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99.documents were identiﬁed. Nine best practices were developed,
including the following: provide a rationale for measuring the out-
come and for using a PRO-PM; describe the context of use; select a
measure that is meaningful to patients with adequate psychometric
properties; provide evidence of the measure’s sensitivity to differ-
ences in care; address missing data and risk adjustment; and provide
a framework for implementation, interpretation, dissemination, and
continuous reﬁnement. Conclusion: Methods for integrating PROs
into performance measurement are available.
Keywords: patient-reported outcome, performance measurement,
PRO-PM, quality.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Background
A foundation for continuous quality improvement is to measure
and compare care across practices and providers to translate
successful management strategies to others [1]. Performance
measurement has traditionally relied on routinely collected
clinical information such as rates of hospital readmission, infec-
tions, procedural complications, survival, or laboratory values.
But the ultimate impact on outcomes experienced by patients,
such as symptoms, functional status, and health-related quality
of life, have rarely been assessed.
Collection and analysis of patient-reported outcome (PRO)
measures is increasingly considered a standard approach for
evaluating these experiences [2–5]. A PRO is deﬁned as informa-
tion about the status of a patient’s health condition that comesdirectly from the patient, without interpretation of the patient’s
response by a clinician or anyone else [3]. A patient-reported
outcome measure (PROM) is a questionnaire used to elicit
information directly from respondents. Inclusion of patients’
direct reports about how they feel and function in quality
assessment programs through the use of patient-reported out-
come-based performance measures (PRO-PMs), and particularly
in accountability and value-based payment initiatives, would
increase the patient-centeredness of these activities [6–8]. PRO
measurement is already common in clinical trials and is of rising
interest in comparative effectiveness research, routine clinical
practice, and electronic medical record systems [9–14].
Beyond patient-centeredness, there are additional rationales
to include PROs in performance measurement. Recent data
suggest that patients’ self-reported symptoms and health statusociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 9 3 – 5 0 4494are associated with the use of medical services (e.g., emergency
room visits and hospitalizations), costs, outpatient medication
compliance, and survival [15–18]. The process of patient self-
reporting itself can improve symptom management, quality of
life, communication, and satisfaction with care [19–22]. Moreover,
symptoms and functional status impairment are far more com-
mon than serious complications of treatment, such as hospital-
izations or death [23]. As the ultimate end users of services,
patients selecting a treatment or provider may have interest in
outcomes based on previous reports of patients like themselves.
There is currently limited understanding in the PRO method-
ology community about performance measurement procedures,
and a similarly limited understanding in the performance meas-
urement community about methodological challenges involved
with developing, administering, and analyzing PRO data. There-
fore, there is a need for a practical blueprint to bring these two
ﬁelds together and describe methodological best practices for
developing, testing, implementing, and interpreting PRO perform-
ance measures that can be used as criteria by measure developers
and credentialing organizations to evaluate candidate measures.Methods
Technical Expert Panel
The American Medical Association–convened Physician Consortium
for Performance Improvement, which has overseen the speciﬁcation
and testing of health care performance measures in the United
States for more than 10 years, assembled a Technical Expert Panel to
develop methodological best practices for guiding the development
and evaluation of PRO measures in performance evaluation. The
panel consisted of experts in performance measurement, PROs,
clinical research, health services research, as well as clinical practi-
tioners and patient representatives (represented by the authors of
this article). By design, the panel’s focus was restricted to traditional
domains measured by PROs, including symptoms, functional status,
and health-related quality of life, and did not encompass patient-
reported health-related behaviors or satisfaction with care (some-
times referred to as patient-reported experience measures, e.g.,
patient perceptions of clinic wait times or staff attentiveness), which
are related but distinct areas of measurement with a more extensive
history in performance evaluation [24–27].
Environmental Scan
The panel ﬁrst completed an environmental scan (including a
structured literature review) of existing pertinent initiatives using
PROs for quality assessment (“use cases”), and related methods
guidance documents. The purpose of ﬁnding use cases was both
to evaluate the current state of this ﬁeld and to identify areas
warranting best practice recommendations.
The literature review was initially conducted in January 2012
and updated in April 2013, via the PubMed electronic database
consisting of two searches, the ﬁrst focused on published reports
of research using PROs to assess performance and the second
focused on existing salient guidance documents. Search terms
are listed in the Appendix in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.02.018.
Identiﬁed publication titles and abstracts were reviewed by two
members of the panel and categorized independently as not
relevant, maybe relevant, or relevant, with citations considered not
relevant by both researchers eliminated and remaining citations
presented to the panel for evaluation. Relevance was based on two
required criteria: 1) elicitation of information about symptoms,
functional status, or health-related quality of life directly from
patients using PRO measures and 2) an objective of measuring orimproving performance/quality of care delivery. Subsequent steps
included assessment of the quality of each identiﬁed study and
review of references to ﬁnd additional potentially relevant articles.
The environmental scan also consisted of a Google search
using permutations of the same terms, which were reviewed in
real time for performance measurement initiatives using PROs, as
well as existing PRO guidance documents. These searches were
supplemented by results of reports contracted by the Patient-
Centered Outcomes Research Institute, which are publicly avail-
able [28,29], and distribution of an e-mail inquiry to an assembled
list of investigators involved in PRO research and performance
measurement research.
Identiﬁed use cases were reviewed by the panel—with direct
communication with investigators whenever possible—to identify
the design and measures used for each initiative. “Key ﬁndings”
were assembled for each use case on the basis of published data
and investigator communication, encompassing the a priori
selected areas of sample size, recruitment and response/retention
rates, project duration, and observed results. “Lessons learned”
were assembled encompassing the a priori selected areas of bias
and adjustment, compliance and missing data, and feasibility.Results
Use Cases and Guidance Documents
Of 21,342 titles identiﬁed by the literature search, 6 publications
were identiﬁed that described initiatives in which PROs were
used in performance evaluation [30–35]. Three additional rele-
vant initiatives were identiﬁed via the Google search [36–38] and
an additional four via the e-mail distribution [39–42]. These 13
use cases are described below and in Table 1, including key
ﬁndings and lessons learned.
A classiﬁcation challenge in identifying use cases is that there
are many initiatives using PROs in clinical practice, in observa-
tional research/comparative effectiveness research, or in inte-
grating PROs with electronic health records. Although these
projects include closely related design elements and can be
instructive, they are not performance-improvement oriented
per se and were therefore excluded from the analysis. Con-
versely, there are programs that incorporate measures in which
patient experiences such as pain are expected to be elicited by
providers from patients and documented, but do not require a
speciﬁc PRO measure to be used. To be included in the use cases,
an example had to include not only the administration of PRO
measures but also a research design intended to measure
performance. It is recognized that other use cases exist that were
not included, and the panel felt that the identiﬁed cases provided
a sufﬁcient basis for developing best practices.
Beyond the use cases, 10 PRO methodological guidance docu-
ments pertaining to other health care areas were identiﬁed and
considered by the panel in establishing best practices [3–5,43–48].
These documents encompass both regulatory and nonregulatory
uses of PRO measures largely in the clinical research context.
Analysis of Use Cases
Overall, the use cases and guidance documents underscore that
PROs are appropriate when information sought is best known by the
patient, for example, symptoms. Outcomes and analysis results
should be important and meaningful to patients in a prespeciﬁed
target population in a prespeciﬁed context of use. Similarly, meas-
ured outcomes should be sensitive to changes in clinical practice
and relevant to clinicians and other decision makers (i.e., action-
able). If an outcome cannot be improved by a change in practice, it is
likely not appropriate for performance measurement.
Table 1 – Example use cases identiﬁed via literature and landscape overviews, using patient-reported outcomes in performance evaluation projects or
programs.*
Name Design Measures Findings Lessons learned
1. English National Health
Service’s (NHS’s) PROMs
Program [36,53]
All providers to English NHS
patients undergoing elective
total hip replacement, total knee
replacement, varicose vein
surgery, and inguinal hernia
repair required to offer baseline
preprocedure PRO questionnaire
and postprocedure PRO
questionnaire after 3 (varicose
vein and hernia) or 6 (hip and
knee replacement) mo
EQ-5D, Oxford Hip Score, Oxford
Knee Score, Aberdeen Varicose
Vein Questionnaire,
postoperative questions about
complications and single
transitional items on overall
view of results
Between April 2009 and March 2011,
485,199 eligible patients with
329,841 preoperative
questionnaires returned (68%
recruitment rate), and 314,488
postoperative questionnaires
mailed out with 253,135 returned
(81% response rate). Overall
improvements observed across
patients. Comparisons of
performance conducted at
“hospital trust” level rather than
single hospital or single provider
level (many hospital trusts
consist of only one hospital)
 Recruitment rates higher for more
major surgery (80%) than for
minor procedures (50%)
 Recruitment bias disfavors
patients who are nonwhite, have
lower socioeconomic status, and
are older and varies considerably
between sites (20%–100%),
necessitating case-mix
adjustment in analyses
 Response bias disfavors patients
who are nonwhite, younger, and
male, have lower socioeconomic
status, and with more
comorbidity. This risks
underdetecting poor quality
because patients with worse
outcomes may be less likely to
return a questionnaire
 For major surgery, disease-speciﬁc
PROs delineate providers as above or
below average performance, with
correlation with generic health state
measures. However, ratings of some
providers depend on the choice of
the measure
 Mandatory systemwide
participation optimizes
response rates
2. Postprostatectomy quality
assessment program [30,54]
Patients returning for follow-up after
radical prostatectomy for localized
prostate cancer administered
online questionnaire at home at
prespeciﬁed time points.
Comparisons of performance are
conducted at the individual
provider level, with an electronic
dashboard showing surgeons
their risk-adjusted results
compared with those of their
colleagues. Patients can access
graphs showing progress over
time in comparison to similar
patients
15 validated items pertaining to
urinary, erectile, and bowel
dysfunction, as well as overall
quality of life
Since 2010, more than 2000 men
have completed more than 5000
questionnaires. Compliance is
75%, with imputation techniques
providing data for 85% of the
patients. Investigations of
surgical techniques at bladder
neck prompted by observation of
better symptomatic results by
some surgeons
 Individual providers incented to
participate because obtaining PROs
before a clinic visit can streamline
the consult-
ation; providers can privately
compare their own outcomes with
those of others and track
performance over time
 Critical driver of high patient
compliance is that patients know
that their questionnaire responses
are seen by the doctor and used in
the clinical consultation
 Electronic administration of
questionnaires pushed out via
continued on next page
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Table 1 – continued
Name Design Measures Findings Lessons learned
automated e-mails, with backup
data collection via staff-
distributed iPads in clinics,
optimizes compliance
 Electronic PRO system is
inexpensive
 PROs obtained for clinical purposes
can be used as end points of
observational and experimental
research
3. Centers for Medicare & Medicaid
Services (CMS)-approved
registry for percutaneous
transcatheter aortic valve
replacement (TAVR) coverage
[39,55]
In 2012, the CMS approved a
National Coverage
Determination (NCD) for TAVR.
The NCD permits coverage at
qualiﬁed sites using an FDA-
approved device for FDA-labeled
indications, and requires all
patients to be included in a
national TAVR registry. The STS/
ACC TVT Registry is the ﬁrst
approved registry for this
purpose, and was developed by
the Society of Thoracic Surgeons
(STS) and the American College
of Cardiology (ACC)
Kansas City Cardiomyopathy
Questionnaire (KCCQ) Short
Form
Public program speciﬁcations require
the inclusion of patient-reported
outcomes. The prosp-
ective registry launched in Sum-
mer 2012 with participation
required for CMS reimbursement
 Program demonstrates CMS
interest in understanding patient
symptom experience and self-
reported health status
 Compliance and results pending
(registry recently launched). Data
anticipated to benchmark
performance and identify patient
and operator/center sources of
variability, and characterize the
symptom burden of patients
undergoing TAVR
 Program will reﬂect the feasibility
of collecting data about how
patients feel and how they
improve after treatment as a
component of CMS-required
evidence
4. Diabetes pay-for-performance
PRO Evaluation [31]
Cross-sectional telephone
interview to measure quality of
care for patients with diabetes
mellitus in pay-for-performance
program. Newly enrolled
patients (o3 mo in program)
compared with long-term
participants (41 y in program)
Satisfaction, compliance, lifestyle/
habits (exercise, diet), and self-
care questionnaire
46% response rate with 1796
respondents with complete
information (1238 case group, 558
control group). Imputation
methods used. Long-term
participants had better outcomes
than did new enrolle-
es including self-care (including
foot care), exercise, diet,
medication compliance, and
satisfaction
 Range of patient-reported metrics
includes medication compliance,
self-care, and lifestyle, which can
be used to evaluate performance
 Case-control design is feasible in
this context
 Cross-sectional design is feasible,
although methods to enhance
response rates might minimize
missing data
5. Dartmouth-Hitchcock Spine
Center project [32,56]
Patients complete 30-min online
questionnaire at baseline and
before each follow-up visit.
Summary reports with
Symptom, functional status/
activity, weakness, employment
status, and lifestyle
questionnaire. Patient-reported
All spine clinic patients participate.
Data shared at the patient and
provider level to guide clinical
 Minimize response burden for
patients by using brief items and
questionnaires that are valid,
reliable, and sensitive to change
continued on next page
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longitudinal trends given to
providers. Population-level data
reported publicly online
including the proportion of
patients who experience
improved pain and functioning
after surgical or nonsurgical
interventions, as well as the
proportion of patients with
numbness and/or weakness
data combined with other
clinical and cost outcomes in
analyses
practice, and at the institutional
level for public reporting
over time
 Questions should have clear
purpose, be salient to patients and
care teams (i.e., match needs and
preferences), and be actionable
 Summary reports for patients and
clinicians enhance engagement
 Collaboration with key nonclinical
stakeholders (employers,
purchasers, researchers, patient
advocates) and ﬁnancial
incentives or cost-sharing can
enhance adoption and use
 Importance of case-mix
adjustment
6. Swedish Rheumatology Quality
Register [37,56]
Patients with rheumatologic
illnesses being treated at
participating clinics complete a
10–15-min questionnaire (paper
or online) before clinic visits.
Summary reports reviewed by
patients and providers at visits.
Data linked to national EHR
system
Pain, swollen and/or tender joints,
general well-being, daily
activities, health state (EQ-5D),
ability to work
Program operating since 1995. By
2012, 64 clinics participating,
with 25 clinics using online
forms. Data shared at the patient
and provider level to guide
clinical practice, and at the
national level for comparing
change scores over time between
practices
 Migration to electronic system
from paper is feasible but requires
local engagement
 Integration of electronic PROs with
a national EHR system is feasible
 Data collected to enhance clinical
practice and patient-provider
communication can also be used
to compare performance between
clinics
 Importance of case-mix
adjustment
7. Boeing Intensive Outpatient
Care Program (IOCP) pilot project
[40]
Patients participating in a
purchaser-sponsored patient-
centered medical home pilot
program complete questions
about physical and mental
health
Physical and mental functioning
questions, and patient-reported
employment information
Starting in 2007, 740 employees and
dependents enrolled, with 15%
improvement in physical
functioning scores, 16%
improvement in mental
functioning scores, and 56%
improvement in patient-reported
missed workdays
 Patient-reported data reﬂect
improved quality of care and
correlate with other metrics of
performance
 Feasible to integrate PROs into
performance-improvement
measurement efforts
8. Mastectomy and Breast
Reconstruction (MBR) Audit [38]
All adult women in England and
Wales undergoing mastectomy
and/or breast reconstruction for
breast cancer complete
questions about satisfaction
with results of surgery,
satisfaction with provider(s),
symptoms, sexual function, and
quality of life longitudinally
BREAST-Q Between 2008 and 2009, 18,216
women aged 16 y and older
enrolled with follow-up data now
collected 3 and 18 mo after
surgery. At 18 mo, among women
undergoing mastectomy without
breast reconstruction, 83% were
satisﬁed with how they looked
clothed and 42% unclothed vs.
women undergoing immediate
reconstruction among whom 90%
were satisﬁed clothed and 59%
unclothed vs. women undergoing
delayed reconstruction among
 Context-speciﬁc questions
designed for a particular patient
population and procedure
provides meaningful information
to advise future patients and
decision makers
 Feasible to implement a universal
longitudinal PRO data collection
initiative in a targeted population
continued on next page
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Table 1 – continued
Name Design Measures Findings Lessons learned
whom 93% were satisﬁed clothed
and 76% unclothed
9. Minnesota Community
Measurement Depression and
Orthopedic Measures [41]
State-mandated program for
primary care and psychiatric
practices across Minnesota to
collect and submit longitudinal
patient depression scores via
secure EMR portal, and pilot for
state-mandated program for
orthopedic and neurosurgical
practices across Minnesota to
collect and submit longitudinal
patient functional status scores
via secure EMR portal
PHQ-9 (for depression program);
Oxford Knee Score, Oswestry
Disability Index, VAS Pain Scale
(for orthopedic program)
For depression program, since 2009,
patients have reported baseline
and follow-up depression scores
at 6- and 12-mo time points (1
mo). Currently, 80% of eligible
Minnesota practices participate.
Six-month depression remission
rates remain low overall (6%
statewide), with some clinics
achieving higher rates (15%–24%).
Practice-level support resources
for patient care management and
between-visit communication
associated with higher remission
rates. Six-month follow-up rate is
25% (N ¼ 75,953) but improving
annually. Orthopedic program
currently in data collection phase
 Primary care clinicians accept
depression score collection and
reporting
 Many patients are lost to follow-
up, suggesting need for backup
data collection methods
 Minnesota Health Reform
mandated the collection of this
measure from all physician clinics
in the state of Minnesota (primary
care and psychiatry). Before this
point in time, 70% of the clinics
participated voluntarily
 The PHQ-9 tool was relatively easy
for software vendors to add to the
EMR, easing data collection and
extraction burden. PHQ-9 coded
for LOINC, which supports
eMeasure speciﬁcations
10. Medicare (CMS) Health
Outcomes Survey (HOS) [33,57]
Administered by the CMS, with
assistance by the National
Committee for Quality
Assurance (NCQA). All managed
care plans with Medicare
Advantage contracts must
participate, with a goal to collect
data toward quality
improvement, accountability,
and public reporting, ultimately
as part of the Five-Star Quality
Rating system for the Medicare
Advantage Plans
HOS (includes speciﬁc patient-
reported items to assess
selected symptoms, functional
status, mental health,
comorbidities, and other
questions toward case-mix and
risk adjustment)
Since 1998, the HOS has been
administered annually to a
random sample of Medicare
beneﬁciaries from each
participating Medicare
Advantage Organization, with
repeat survey administration 2 y
later, with an annual cohort
sample size randomly chosen in
those plans over 1000.
Compliance rates range between
about 50% and 85% by year of
cohort. Performance of plans is
classiﬁed for a mental summary
score and physical summary as
being better, same, or worse than
expected. HOS survey results are
included as part of the Medicare
Advantage Quality and
Performance Plan Ratings System
to be used by the CMS as the
basis for quality bonus payments
 A payer-developed PRO
performance evaluation strategy is
feasible
 PRO data can be combined with
other performance measures
 PRO data can be used within the
context of a pay-for-performance
program
 Two-year follow-up is feasible,
although response rates vary from
year to year
 Patient self-reporting can be used
continued on next page
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11. Cancer Care Ontario
Chemotherapy Symptoms [34]
Across the Canadian province of
Ontario, internet kiosks installed
in outpatient oncology clinics
for patient voluntary symptom
self-reporting at clinic visits
Edmonton Symptom Assessment
Scale (ESAS)
Program administered in 2006.
Performance measures included
proportion of patients
completing the ESAS at initial
and follow-up visits; proportion
of patients with severe
symptoms whose symptoms are
improved at subsequent
assessment; proportion of
patients self-reporting
depression who are further
assessed or referred for
psychosocial resources within 72
h. Within 1 y of implementation,
improvements seen in symptom
screening rates and symptom
control
as both a process (% completing
ESAS) and an outcome measure
(symptom improvement over
time; timely referral) in the same
implementation
 Regional entities overseeing care
can be engaged by a central
administration to implement a
systemwide program
 Compliance rates may not be
optimal with “voluntary” patient
reports via clinic-based kiosks.
Patients may have other priorities
at clinic visits, and those too ill to
attend visits are missed
12. Managed Health Care
Association (MHCA) Outcomes
Management System
Consortium Asthma Survey [35]
Cross-sectional survey mailed to
adult asthma patients enrolled
in 12 managed care
organizations
Questionnaire including asthma
symptoms and overall health
status items
Survey mailed to 1954 patients at a
single time point. Primary ﬁnding
related to patient-reported data
is greater likelihood of improved
asthma symptoms when
treatment is under the
supervision of a specialty-trained
(i.e., pulmonologist) rather than
generalist physician
 Cross-sectional surveys can
provide between-practitioner–
level data
 Consortia of payer organizations
may be used as a mechanism for
administering surveys to patients
13. English Heavy Menstrual
Bleeding Audit [42]
All adult women in England
attending NHS gynecological
outpatient clinics for heavy
menstrual bleeding complete
questions about symptoms,
functional status, and health-
related quality of life. Mailed
questionnaire 1 y later
Uterine Fibroid Symptoms and QoL
Questionnaire (UFS-QOL), EQ-5D
Baseline questionnaires
administered to 15,812 women
between February 2011 and
January 2012 (recruitment rate
30%), with follow-up
questionnaires sent 1 y later; 148
of 154 hospital trusts
participating. One-year follow-up
underway
 Recruitment of patients referred to
specialist outpatient clinic much
lower than recruitment of those
undergoing surgical procedure/
treatment (compared with other
national England programs)
 Difﬁcult to determine recruitment
rate in outpatient clinic because
hospital administrative data on
outpatients are limited (no
diagnostic data) compared with
data on inpatients
BREAST-Q, Breast Reconstruction Questionnaire; EHR, electronic health record; EMR, electronic medical record; EQ-5D, EuroQol ﬁve-dimensional questionnaire; FDA, Food and Drug
Administration; LOINC, Logical Observation Identiﬁers Names and Codes; PHQ-9, Patient Health Questionnaire-9; PRO, patient-reported outcome; PROMs, patient-reported outcome measures;
TVT, Transcatheter Valve Trial; VAS, visual analogue scale.
* It is recognized that this list may not be exhaustive.
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Table 2 – Methodological best practices and associated considerations for developing and evaluating proposed
patient-reported outcome performance measures (PRO-PMs).
Best practice Considerations Corresponding National Quality
Forum (NQF) measure evaluation
criteria*
1. A rationale for measuring the
outcome should be described
 Is a knowledge gap described and
justiﬁed?
 Is there evidence that the outcome is
meaningful and important to patients,
caregivers, and/or other stakeholders?
 How does patient self-reporting in
particular address the gap?
 Are patients the most appropriate source
of information?
 Evidence, Performance Gap, and
Priority (Impact)—Importance to
Measure and Report
2. The intended context of use
should be described and
justiﬁed
 Is the intended context of use clearly
described and justiﬁed?
 How is information from the measure
expected to inform change in practice to
improve performance in the intended
context of use?
 How will the nominated measure
complement other measures to improve
understanding of performance in the
intended context of use?
 Is there variability in the outcome at the
practice or practitioner level?
 Evidence, Performance Gap, and
Priority (Impact)—Importance to
Measure and Report
 Comparison to Related or Competing
Measures
3. The measure should be
adequately developed for the
intended context of use (or a
similar context of use), including
demonstration of
meaningfulness and importance
to patients as well as adequate
psychometric properties
 Is the underlying concept to be measured
clearly identiﬁed (e.g., postchemotherapy
nausea)?
 Is there prior or planned qualitative work
in a patient population similar to the
intended context of use demonstrating
understanding of terminology and
mapping of the terminology to the
underlying concept(s) of interest?
 Is there evidence of adequate
psychometric properties of the measure,
including construct validity and
reliability; meaningfulness of score
changes in a comparable population; and
reasonableness of the recall period?
 Reliability and Validity—Scientiﬁc
Acceptability of Measure Properties
4. There should be prior or planned
work using the measure in the
intended context of use (or a
similar context of use),
demonstrating that it is
sensitive to change and
clinically actionable
 Has the measure been shown to detect
changes over time or differences between
known patient groups, practices, and/or
procedures?
 Does the measure detect change in
clinical action(s)?
 Is there evidence that there is not a ﬂoor
or ceiling effect of the measure in the
intended context of use?
 Feasibility
 Usability and Use
5. There should be a recommended
implementation strategy for the
measure in the intended context
of use
 Is there a rationale for an administration
mode (e.g., paper, electronic) and
schedule (e.g., timing of follow-up
evaluations)?
 Is there a plan to maximize recruitment
and response rates (e.g., backup data
collection plan for nonrespondents)?
 Is proxy or surrogate reporting considered
allowable?
 Is there a plan to accurately identify
patients in the target population and
calculate the denominator (i.e., number
of people who were asked to complete
the measure)?
 Feasibility
continued on next page
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Table 2 – continued
Best practice Considerations Corresponding National Quality
Forum (NQF) measure evaluation
criteria*
6. There should be a recommended
analysis plan, including risk-
adjustment strategy, missing
data approach, and power
calculation
 Is there a well-justiﬁed a priori risk-
adjustment or stratiﬁcation strategy
based on evidence?
 Is there a plan to adjust analyses for case
mix, recruitment bias, and response bias?
 Is there a plan for imputing missing data,
with sensitivity analyses?
 What sample sizes are necessary for
planned analyses?
 Reliability and Validity—Scientiﬁc
Acceptability of Measure Properties
7. There should be a recommended
framework for interpreting
results, including unit(s) of
analysis and meaningful score
thresholds
 What unit of analysis is recommended (e.
g., hospital system, hospital, individual
practice, individual practitioner, and
patient-level)?
 What metrics should be used to reﬂect
performance (e.g., proportion of patients
achieving a speciﬁc score change;
proportion of providers who are outliers)?
 How are results of different PRO
measures that may not agree with each
other considered?
 Reliability and Validity—Scientiﬁc
Acceptability of Measure Properties
8. There should be a recommended
approach for reporting and
disseminating results
 Is there a suggested approach for
packaging and presenting reports to
practices, providers, and/or patients?
 Usability and Use
9. There should be a recommended
approach for assessing the
impact of the measurement
approach itself during/after
implementation
 How can the ability to distinguish
between units of analysis be assessed?
 How can the risk assessment strategy be
assessed or revised?
 Comparison to Related or Competing
Measures
* Details available from www.qualityforum.org/docs/measure_evaluation_criteria.aspx.
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sensitivity to within- and between-practice variations, appropri-
ate unit(s) of analysis, and barriers to implementation, as well as
continued evaluation of programs to improve implementation
strategies, is also emphasized.
Use of measures with well-established psychometric proper-
ties is a common theme in the identiﬁed use cases and partic-
ularly in guidance documents, including qualitative and
quantitative data to establish that patients in a target population
understand terms and that terms map to underlying outcomes of
interest; construct validity; reliability; sensitivity to change over
time; appropriate recall period; meaningfulness of score thresh-
olds and changes to patients; and adequacy of cultural, linguistic,
and mode adaptation as needed.
The availability and use of methods to optimize response
rates and minimize missing data is an almost universal theme,
with approaches to optimize response rates including centralized
data collection, reminder mechanisms, mandatory collection of
information in practices (rather than voluntary or subpopulation
collection), partnership with providers and communities, and use
of proxy/surrogate reporting.
Most use cases include a risk/case-mix adjustment strategy.
In some instances, adjustment for response rates is considered in
analyses to avoid response bias; that is, patients with worse
outcomes are less likely to return a questionnaire, so those
providers who are most vigilant about obtaining follow-up ques-
tionnaires may recover a higher proportion of responses from
sicker individuals with worse outcomes, making their results look
worse if analyses are unadjusted.An a priori plan for data analysis, interpretation, and dissem-
ination is emphasized. This includes a plan for handling missing
data using imputation methods because patient-reported data are
often missing not at random [49]. Other issues include dealing
with multiple end points/comparisons, measuring cross-sectional
differences versus changes over time, adequacy of sample size and
potential overpowering, and consideration of outliers in analyses.
Most of these issues are not unique to PRO-based analyses.Best Practice Recommendations
Five a priori areas of review guided the panel in analyzing use
cases and guidelines to extract best practices that facilitate the
development of clinically meaningful and scientiﬁcally robust
performance measures: selection of outcomes, development/
selection of metrics, implementation, analysis, and reporting/
dissemination. This analysis yielded nine best practices that are
presented in Table 2 along with speciﬁc questions that can be
considered to determine whether a measure abides by the
recommendations. Panel agreement was unanimous on each;
reﬁnements were made on the basis of public comment
(described below). The best practices were approved by the
Physician Consortium for Performance Improvement Measures
Implementation and Informatics Committee.
The panel concluded that a PRO measure should be consid-
ered within the proposed context of use and implementation
strategy. Therefore, information about these should be provided
with candidate measures. It is acknowledged that not all the
Table 3 – Example of how the best practices can be
used to develop a measure.
A large network of community oncology practices is interested in
understanding differences between practices in
postchemotherapy nausea control as a potential quality
measure. The rationale for this measure is published cross-
sectional data about rates of nausea, and about variable
compliance with published antiemetic guidelines (best practice
1). The purpose of the measure is to understand whether there
are variable rates of nausea control between practices that
might be improved through educational programs or feedback
to providers (best practice 2). An existing nausea measure from
the National Cancer Institute’s (NCI’s) PRO-CTCAE symptom
library is selected on the basis of published qualitative and
quantitative data in a similar community practice context,
providing evidence that the measure evaluates a symptom that
is important and meaningful to patients, with acceptable
validity and reliability. Relevant permissions from the NCI are
obtained (best practices 3 and 4). A multidisciplinary planning
panel, including patient representatives, identiﬁes the pertinent
population as patients receiving moderately or highly
emetogenic chemotherapy according to existing criteria (best
practice 2). It is determined on the basis of a literature review to
use an automated telephone system (IVRS) with live interviewer
backup to assess symptoms at baseline (and to collect baseline
data for risk adjustment), as well as daily following
chemotherapy for 7 d (best practice 5). The proportion of
patients experiencing moderate and severe nausea at more than
one time point following chemotherapy at the practice level is
chosen as the a priori primary end point, with risk adjustment
for age, comorbidities, stage of cancer, number of prior lines of
chemotherapy, time since diagnosis, baseline quality of life (via
a PROMIS single measure), baseline nausea, and comorbidities
(best practices 6 and 7). Exploratory analyses will be used to
evaluate alternative end points in the analysis phase and reﬁne
the risk adjustment model. A sample size is determined by a
biostatistician on the basis of published effect sizes for similar
patients, accounting for anticipated missing data and attrition
(best practice 6). Results will be fed back to practices with a
planned onsite educational program offered to sites with lower
performance (best practice 8). Follow-up assessment of practices
following educational programs is planned to assess the impact
of the programs, in addition to eliciting provider feedback about
the program (best practice 9).
IVRS, interactive voice response system; PRO-CTCAE, Patient-
Reported Outcomes version of the Common Terminology Criteria
for Adverse Events; PROMIS, Patient-Reported Outcomes Measure-
ment Information System.
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for all approaches, especially in these early days of developing
and testing PRO performance measures. But the considerations
should be addressed, and some may be tested within early
implementation or pilot work.
The panel concluded that an actionable PRO measure is one that
can identify patients for whom changes in care might be warranted
and detects changes in outcomes after treatment. Demonstration of
this capacity is advisable before widespread implementation.
Because the use of PROs in performance evaluation has been
uncommon in the past, it is acknowledged that research in other
related contexts may be relied upon initially for such evidence, such
as use of a measure in clinical trials or comparative effectiveness
research. When adapting an existing PROM for use in performance
measurement (e.g., a measure initially developed for use in clinical
research), it should be considered whether it 1) assesses outcomes
that are meaningful in the population/context of interest and are
actionable; 2) has been found understandable to patients in qual-
itative assessments; 3) demonstrates validity, reliability, and respon-
siveness; and 4) is feasible to implement (e.g., is not excessively
lengthy, has available language translations if necessary, and can be
administered electronically if necessary). Speciﬁc approaches for
adapting PROMs into PRO-PMs have previously been described by
the National Quality Forum (NQF), as well as details about the
distinctions between PROs, PROMs, and PRO-PMs [50].
The goal of measuring PROs and rewarding performance on the
basis of PROs is to encourage clinicians and organizations to adopt
procedures that improve outcomes experienced by patients. Accu-
rate measurement of PROs will be hindered if variation in perform-
ance among providers primarily reﬂects differences in the underlying
populations served and adjustment methods are not used. Quantify-
ing changes in scores over time compared with baseline, rather than
relying on cross-sectional analyses, allows patients to serve as their
own controls and accounts for baseline health status. It is acknowl-
edged that risk-adjustment approachesmay be reﬁned over time in a
particular program and that risk adjustment may be deemed
unnecessary in some contexts (which should be demonstrated with
empiric evidence). A practical example of how the best practices may
be used to develop a measure is provided in Table 3.
Harmonization with NQF White Paper and Public Comment
During the period of development of these best practices, the NQF
produced a white paper outlining a pathway for PRO-PMs [50,51].
Because of the importance of the NQF as the major US organ-
ization for endorsing performance measures, it was considered
important by the panel to harmonize the panel’s and the NQF’s
efforts. Therefore, the panel’s best practices and the NQF path-
way were mapped to each other in a table to assist measure
developers who may wish to understand how the different
recommendations relate to each other (Table 2).
A draft of the best practice recommendations was posted on
the Physician Consortium for Performance Improvement Web
site during a 3-week public comment period. Input was elicited
for each individual recommendation, and overall. The public
comment process yielded feedback from 15 national and interna-
tional organizations. No major substantive changes were sug-
gested. Each comment was reviewed in a panel meeting with
individual responses generated, and alterations to the recom-
mendations were made on the basis of panel consensus.
Purposes for Using PRO-PMs
On the basis of the use cases, the panel identiﬁed ﬁve purposes for
which PRO measures may be used in performance evaluation
(Table 4). An underlying premise is that PROs should be used when
information sought is best known by the patient, for example,symptoms. This information can be used along with information
from other sources, such as the medical chart. The table provides
illustrations of how each of the ﬁve purposes could be pursued in
speciﬁc contexts of use. These purposes are not mutually exclu-
sive, and can be addressed together in a given assessment
program, sometimes within the same data collection strategy.Discussion
This article presents use cases of PRO-PM development and
implementation that along with several identiﬁed guidance
documents informed the development of best practices. A group
of purposes for developing PRO-PMs and using the best practices
is also presented to guide measure developers in thinking about
how PROs might best be used in a given context.
Table 4 – Various purposes for measuring patient-
reported outcomes (PROs) to assess performance,
and examples.
Purpose of PRO measure Example
A. Assess appropriateness of
patients administered a
particular treatment
Measure the proportion of
patients with baseline
angina before angioplasty
B. Assess appropriateness of
treatment administered to
particular patients
Measure the proportion of
patients with
postchemotherapy nausea
for whom appropriate
antiemetics are prescribed
C. Assess impact of clinical
and/or self-care
management administered
for a particular condition
Measure the proportion of
patients with asthma
experiencing improvement
in dyspnea at prespeciﬁed
time points
D. Support or complement
other performance
measures
Measure postprostatectomy
erectile dysfunction and
urinary incontinence in
combination with surgical
margins and local
recurrence rates
E. Assess the process of using
PROs in clinical and/or self-
care practice
Measure the proportion of
patients from whom direct
reports of salient symptoms
are collected at prespeciﬁed
time points
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of a proposed PRO performance measure warrants more than
simply understanding whether the measure is valid and reliable—
it requires an overall measurement strategy that takes into account
the intended context of use, population, and meaningfulness to
patients. It is acknowledged that at the current time, there is limited
experience with these approaches, and the best practices are
anticipated to evolve as evidence accumulates. It is also recognized
that overly stringent standards should not hinder the endorsement
of projects that may enrich knowledge and advance this area. Not all
best practices will be abided by, or are appropriate, in all proposals.
Among the ﬁve identiﬁed “purposes” for collecting PRO data in
performance measurement in Table 4, the ﬁfth, “Assess use of
patient-reported outcomes to enhance clinical practice,” is per-
haps the most novel. Although there is increasing interest in
routinely collecting PRO measures to enhance clinical manage-
ment, this is still not standard practice [9,12,14]. Many opera-
tional questions remain however: how should this information
optimally be collected (paper vs. electronic; in waiting rooms vs.
from home between visits); when should initial and follow-up
assessments be conducted; who should review this information
and when; what speciﬁc information should be collected; should
clinical actions resulting from this information be tracked? These
questions merit future research, and approaches are expected to
vary depending on the intended context of use of a measure.
Moving forward, there are a number of challenges, some
which are inherent to PRO measurement, and some that apply
to performance measurement more broadly. Maximizing recruit-
ment and response rates (particularly from the sickest and busiest
patients) and analyzing missing data are perennial challenges in
PRO assessment [49]. Poor performance may be underdetected if
ill patients systematically do not self-report, and sites that more
effectively encourage sicker patients to return questionnaires may
appear to have worse quality, unless analyses are adjusted for
response bias. An additional challenge is identifying formats forreporting ﬁndings in a manner that is accessible, interpretable,
meaningful, and actionable across stakeholders [52].Conclusions
Enthusiasm to elicit the patient perspective in performance
evaluation is evolving within a broader context of patient-
centeredness in health care delivery, research, and policy [8].
The overall goal of developing best practices for PRO-PMs is to
provide a framework and context-appropriate speciﬁcations for
supporting the development of patient-centered performance
measurement strategies. It is the hope of the authors that these
best practices will encourage future development of rigorous
approaches that help better characterize the impact of care on
the patient experience, and enable mechanisms for improving
that experience across populations.
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